mDetect is focused on revolutionizing the management of metastatic cancers through advanced testing methods that enable oncologists to monitor cancer progression, relapse, and treatment response with greater precision. Their innovative approach utilizes liquid biopsy technology, which allows for the analysis of biomarkers in bodily fluids, providing detailed and personalized data for each patient. This method enhances the ability to track the effectiveness of treatments and make informed decisions regarding patient care.

The company is dedicated to transforming cancer management by offering tools that facilitate a deeper understanding of individual patient profiles. By leveraging advanced testing techniques, mDetect aims to improve outcomes for cancer patients, ensuring that oncologists have access to critical information that can guide treatment strategies. This commitment to personalized medicine underscores mDetect's role in advancing cancer care and improving the overall patient experience.

Canada

The mDETECT tests are highly specific and sensitive blood tests that monitor c tumour burden in cancer (metastatic) patients using targeted methylation marks in circulating tumour DNA (ctDNA). mDETECT can accurately and rapidly determine cancer relapse, progression, and response to therapy to help extend the lives of patients.

mDetect

Company Details